Hoyland or anyone else- what are your thoughts about Benitec doing a potential sub-license agreement with Regenxbio to sell our silence & replace vector technology to their existing customer base?
Below is a Barron's article quote regarding Regenxbio partnerships & royalties...
"Amusa, the Chardan analyst, favors Regenxbio, calling it “the best way to broadly play the emergence of vector-based gene therapy.” The company, based in Rockville, Md., is licensing viral vectors to about 10 partners, including AveXis and Audentes, and will get royalties estimated at about 10% if those treatments are commercialized."
Regenxbio could be an efficient route for Benitec to sell it's silence & replace expertise tech to multiple partners quickly because of Regenxbio established partnerships with many biotech companies..
BLT Price at posting:
19.0¢ Sentiment: Buy Disclosure: Held
